CUTISS AG

We’re excited to share that The Boston Globe covered the story of the first U.S. patient treated with denovoSkin™ at Massachusetts General Hospital, an important milestone we announced last week.   This marks the first time our bi-layer bio-engineered graft has been used under FDA compassionate use for reconstructive surgery, offering new hope to a young patient.   As we continue to advance our innovations and transition to Phase 3 clinical trials with denovoSkin™, our Series C #fundraising round remains open to investors who want to take part in the next stage of growth at CUTISS.   The Boston Globe article: https://lnkd.in/e7xAxp8h   #RegenerativeMedicine #Biotech #Bioengineering #TissueEngineering #ReconstructiveSurgery #Innovation #SeriesC

In 2023, in the UK alone, 9,939 adults and 8,551 children experienced serious burns and scalds. A burn injury is for life. This is why developing treatments that improve healing, reduce scarring, and enhance quality of life is so important. At CUTISS, we’re committed to pushing the boundaries of skin regeneration to offer better outcomes for adult and child burn survivors and those requiring reconstructive skin surgery. Our Series C #fundraising round remains open to investors seeking to support the future of regenerative medicine.   Children's Burns Trust #BeBurnsAware #NationalBurnAwarenessDay #RegenerativeMedicine #Innovation

Milestone news: The first U.S. patient has been treated with denovoSkin™ in reconstructive surgery under FDA compassionate use. This procedure, performed at Massachusetts General Hospital, may offer new hope to a pediatric patient with severe burn scars and contractures.   Following two denovoSkin™ grafting procedures, the patient is recovering well, with a third procedure planned.   We thank the whole team at Massachusetts General Hospital, with special recognition to Rob Sheridan, jeremy goverman and Matthew David Supple   Read our press release for more details: https://lnkd.in/eKxbZ45z   #RegenerativeMedicine #TissueEngineerng #SkinGraft #Innovation #ReconstructiveSurgery #biotechnology 

We’re honored to be selected as one of the most promising Swiss biotechs with the potential to become a future Swiss unicorn! Thank you to this year’s jury of growth investors that made the selection and recognized our groundbreaking work in skin regenerative medicine. Our CUTISS team remains committed to deliver the world’s first personalized and automated skin tissue therapy for patients suffering from severe burns and scarring. Get in touch if you’d like to learn about investment opportunities with us #TOP100SSU #SwissStartups #Innovation #Swisstech

#NEWMEDICALREPORT, Phase 1 data for denovoSkinTM with 5year follow up is now published in the Journal of Burn Care & Research. "Long-term outcomes of a cultured autologous dermo-epidermal skin substitute in children: 5 year results of a phase I clinical trial" During the course of the study, denovoSkinTM continued to be safe, remained stable and practically unchanged, with no sign of fragility, and no tumor formation at clinical examination. Scar quality, captured by applying POSAS, was evaluated close to normal skin. These results are promising and highlight the potential of a life-saving and quality-of-life improving therapy for large skin defects. Phase II readouts are available and follow ups are ongoing in burns and reconstructive, check CUTISS AG newsroom. #KUDOS to all teams involved and to all patients, families and sponsors/supporters. Wyss Zurich Kinderspital Zürich University of Zurich European Commission #treatmentforburns #reconstructivesurgery #regenerativemedicine #innovation

We're excited to be included in L'Agefi's list of 10 game-changing Swiss innovations! 🌟 Read the full article "CUTISS gives burn victims new skin" to get the latest news about our work in revolutionizing skin surgery. Thank you to Sophie Marenne for the visit and wonderful article AGEFI, Nouvelle Agence Économique et Financière #innovation #swisstech #regenerativemedicine #tissueengineering #seriesC #clinicaltrials

Soaring summer temperatures in regions like Nevada and Phoenix can lead to serious skin contact burns and injuries from hot pavements and surfaces. About 40% of patients require skin surgery to remove damaged tissue and cover the area with a skin graft. Some spend weeks in the hospital recovering.   It’s difficult to ignore the severe impacts that such high temperatures can have on regular people. The available treatment options for skin injuries need to expand.   We're committed to advancing skin regenerative medicine to improve skin surgery and recovery outcomes for severe burn patients.   Read the full New York Times article: https://lnkd.in/dTAvEbwF

🚀 Clinical trials update from CUTISS! We’re excited to announce a positive interim analysis on the efficacy of our lead product denovoSkin™ (versus standard of care) from the Phase 2 clinical trial in reconstructive skin surgery. This trial focuses on pediatric, adolescent and adult patients requiring skin grafts in skin reconstructive procedures. denovoSkin™ aims to provide a solution to reduce scarring and therefore improve healing outcomes. “These results confirm our mission to provide access to denovoSkin™ beyond burns, changing the status quo in skin surgery globally,” said Daniela Marino, CEO of CUTISS. “We extend our heartfelt gratitude to all involved in this multicentric trial across Switzerland, Italy, and the Netherlands.” The full data analysis with one-year follow-up results is expected in early 2025. Read our press release for more details: https://lnkd.in/ektSC2ij #RegenerativeMedicine #Innovation #Healthcare #ClinicalTrials #SkinSurgery

We were delighted to participate in the 20th SECA Conference, titled "Value Creation through Innovation”. It’s one of the largest conferences in Switzerland bringing together the private equity, venture capital and corporate finance industry.   Our CEO Daniela Marino participated in the Healthcare Value Creation panel with Chandra P. Leo, Richard Fritschi and Guido Kamann, highlighting our pioneering work in regenerative medicine and its transformative global impact on healthcare.   Thank you to Javier Rivas, FIA CFA for moderating and thanks John Cook, Maurice R.H. Pedergnana and SECA for hosting this enriching conference and to everyone who engaged with us! SECA - Swiss Private Equity & Corporate Finance Association #regenerativemedicine #seca #privateequity #fundraising #innovation #healthcare

🚀 Exciting News from CUTISS! 🚀 We're delighted to announce the first closing of CHF 25 million in our Series C funding round! This funding supports the continued development and path to commercialization of our skin cell therapies denovoSkin™ and Viticell®. A huge thank you to the new US-based co-lead investor and the other Swiss and international investors. This milestone allows us to advance to Phase 3 clinical trials and move closer to bringing our life-changing therapies to patients.   We invite additional investors to join us on our mission to transform skin surgery and improve patient outcomes worldwide. For more details, read our press release: https://lnkd.in/eUVecez2 #RegenerativeMedicine #Biotech #Innovation #FundingNews #SeriesC